miR-181b在胆管癌患者中表达及功能研究

doi:10.3877/cma.j.issn.2095-3232.2020.02.020

中华肝脏外科手术学电子杂志 ›› 2020, Vol. 09 ›› Issue (02) : 186 -190. doi: 10.3877/cma.j.issn.2095-3232.2020.02.020

所属专题：文献；

基础研究

miR-181b在胆管癌患者中表达及功能研究

江哲龙¹, 杨和君², 潘凡², 吕立志³^,^†(

), 江艺²

^1. 350025　福州，福建医科大学福总临床医学院
^2. 350000　福州，联勤保障部队第九〇〇医院肝胆外科
^3. 350025　福州，福建医科大学福总临床医学院；350000　福州，联勤保障部队第九〇〇医院肝胆外科

收稿日期:2019-12-25 出版日期:2020-04-10
通信作者: 吕立志
基金资助:
福建省科技计划项目(2019y0068); 联勤保障部队第九〇〇医院院内课题(2018Q06，2018J02)

Expression and function of miR-181b in cholangiocarcinoma patients

Zhelong Jiang¹, Hejun Yang², Fan Pan², Lizhi Lyu³^,^†(), Yi Jiang²

^1. Fuzong Clinical Medical College of Fujian Medical University, Fuzhou 350025, China
^2. Department of Hepatobiliary Surgery, 900 Hospital of Joint Logistics Support Force of PLA, Fuzhou 350000, China
^3. Fuzong Clinical Medical College of Fujian Medical University, Fuzhou 350025, China; Department of Hepatobiliary Surgery, 900 Hospital of Joint Logistics Support Force of PLA, Fuzhou 350000, China

Received:2019-12-25 Published:2020-04-10
Corresponding author: Lizhi Lyu
About author:
Corresponding author: Lyu Lizhi, Email: 373944554@qq.com

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

江哲龙, 杨和君, 潘凡, 吕立志, 江艺. miR-181b在胆管癌患者中表达及功能研究[J]. 中华肝脏外科手术学电子杂志, 2020, 09(02): 186-190.

Zhelong Jiang, Hejun Yang, Fan Pan, Lizhi Lyu, Yi Jiang. Expression and function of miR-181b in cholangiocarcinoma patients[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2020, 09(02): 186-190.

目的

探讨胆管癌患者中microRNA（miR）-181b的表达和临床意义。

方法

回顾性分析2008年1月至2013年1月中国人民解放军联勤保障部队第九OO医院收治的100例胆管癌患者临床资料（胆管癌组），同时选取100例健康志愿者作为对照组。患者均签署知情同意书，符合医学伦理学规定。其中胆管癌组男61例，女39例；年龄33～80岁，中位年龄56岁。对照组男66例，女34例；年龄30～80岁，中位年龄54岁。采用RT-PCR检测血清和组织样本中miR-181b的表达量，分析miR-181b与患者临床病理特征间的关系及其在诊断和预后中价值。根据胆管癌组癌组织中miR-181b表达量的平均值，将胆管癌组分为miR-181b高表达组和miR-181b低表达组。两组miR-181b比较采用t检验。采用Kaplan-Meier法绘制生存曲线，生存分析采用Log-rank检验。

结果

胆管癌组患者血清miR-181b表达量1.24±0.24，明显高于对照组的0.61±0.13（t=66.59，P<0.05）。胆管癌组癌组织miR-181b的表达量2.31±0.14，明显高于癌旁组织的1.17±0.11（t=34.53，P<0.05）。miR-181b表达与肿瘤直径、TNM分期、淋巴结转移相关（t=-2.10，-2.61，-4.86；P<0.05）。miR-181b低表达组和高表达组3年生存率分别为37.50%、11.76%，差异有统计学意义（χ²=9.007，P<0.05）。

结论

miR-181b在胆管癌患者中呈高表达，且与分期、预后相关，高表达患者预后较差。

关键词: 胆管肿瘤, miR-181b, 预后

Objective

To investigate the expression and clinical significance of microRNA (miR)-181b in patients with cholangiocarcinoma.

Methods

Clinical data of 100 patients with cholangiocarcinoma (cholangiocarcinoma group) admitted to the 900^th Hospital of Joint Logistics Support Force of PLA from January 2008 to January 2013 were retrospectively analyzed, and 100 healthy volunteers were assigned into the control group. The informed consents of all patients were obtained and the local ethical committee approval was received. In cholangiocarcinoma group, 61 patients were male and 39 female, aged 33-80 years old with a median age of 56 years old. In control group, 66 patients were male and 34 female, aged 30-80 years oldwith a median age of 54 years old. The expression levels of miR-181b in the serum and tissue samples were detected by RT-PCR. The relationship between miR-181b and clinicopathological features of patients and its value in the diagnosis and prognosis were assessed. According to the average expression level of miR-181b in the cancer tissues, patients in cholangiocarcinoma group were divided into the miR-181b high expression group and miR-181b low expression group. The expression levels of miR-181b between two groups were compared by t test. The survival curve was delineated by Kaplan-Meier method. Survival analysis was performed by Log-rank test.

Results

The serum expression of miR-181b in cholangiocarcinoma group was 1.24±0.24, significantly higher than 0.61±0.13 in control group (t=66.59, P<0.05). In cholangiocarcinoma group, the expression of miR-181b in cancer tissues was 2.31±0.14, significantly higher than 1.17±0.11 in the adjacent tissues (t=34.53, P<0.05). The expression level of miR-181b was significantly correlated with tumor diameter, TNM staging and lymph node metastasis (t=-2.10, -2.61, -4.86; P<0.05). The 3-year survival rates in miR-181b low- and high-expression groups were 37.50% and 11.76%, respectively, where significant difference was observed (χ2=9.007, P<0.05).

Conclusions

miR-181b is highly expressed in cholangiocarcinoma patients, which is significantly correlated with TNM staging and clinical prognosis. Patients with high expression of miR-181b has poorer prognosis.

Key words: Bile duct neoplasms, miR-181b, Prognosis

表1 癌组织中miR-181b表达与临床病理学的关系(±s)

因素		例数	miR-181b表达量	t值	P值
性别		?	?	0.20	0.84
?	男	61	2.31±0.15	?	?
?	女	39	2.31±0.13	?	?
年龄		?	?	-0.45	0.66
?	<55岁	42	2.30±0.13	?	?
?	≥55岁	58	2.31±0.15	?	?
肿瘤直径		?	?	-2.10	0.03
?	<2 cm	28	2.26±0.10	?	?
?	≥2 cm	72	2.33±0.15	?	?
TNM分期		?	?	-2.61	0.01
?	Ⅰ～Ⅱ期	77	2.20±0.10	?	?
?	Ⅲ～Ⅳ期	23	2.33±0.14	?	?
淋巴结转移		?	?	-4.86	<0.001
?	无	37	2.23±0.16	?	?
?	有	63	2.36±0.09	?	?

表1 癌组织中miR-181b表达与临床病理学的关系(±s)

因素		例数	miR-181b表达量	t值	P值
性别		?	?	0.20	0.84
?	男	61	2.31±0.15	?	?
?	女	39	2.31±0.13	?	?
年龄		?	?	-0.45	0.66
?	<55岁	42	2.30±0.13	?	?
?	≥55岁	58	2.31±0.15	?	?
肿瘤直径		?	?	-2.10	0.03
?	<2 cm	28	2.26±0.10	?	?
?	≥2 cm	72	2.33±0.15	?	?
TNM分期		?	?	-2.61	0.01
?	Ⅰ～Ⅱ期	77	2.20±0.10	?	?
?	Ⅲ～Ⅳ期	23	2.33±0.14	?	?
淋巴结转移		?	?	-4.86	<0.001
?	无	37	2.23±0.16	?	?
?	有	63	2.36±0.09	?	?

图1 miR-181b低表达组和高表达组胆管癌患者Kaplan-Meier生存曲线

[1]	Blechacz B. Cholangiocarcinoma: current knowledge and new developments[J]. Gut Liver, 2017, 11(1):13-26.
[2]	Lewis HL, Rahnemai-Azar AA, Dillhoff M, et al. Current management of perihilar cholangiocarcinoma and future perspectives[J]. Chirurgia, 2017, 112(3):193-207.
[3]	Zhou B, Li Z, Yang H, et al. Extracellular miRNAs: origin, function and biomarkers in hepatic diseases[J]. J Biomed Nanotechnol, 2014, 10(10):2865-2890.
[4]	Zhang C, Wang P, Li Y, et al. Role of microRNAs in the development of hepatocellular carcinoma in nonalcoholic fatty liver disease[J]. Anat Rec, 2019, 302(2):193-200.
[5]	Liu Y, Uzair-Ur-Rehman, Guo Y, et al. miR-181b functions asan oncomiR in colorectal cancer by targeting PDCD4[J]. Protein Cell, 2016, 7(10):722-734.
[6]	Chen Y, Li R, Pan M, et al. MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor[J]. J Neurooncol, 2017, 133(3): 477-485.
[7]	Li D, Jian W, Wei C, et al. Down-regulation of miR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer[J]. Int J Clin Exp Pathol, 2014, 7(11):7672-7680.
[8]	Xia Y, Gao Y. MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2[J]. Biochem Biophys Res Commun, 2014, 447(3):446-451.
[9]	Shin HR, Oh JK, Lim MK, et al. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea[J]. J Korean Med Sci, 2010, 25(7):1011-1016.
[10]	Doherty B, Nambudiri VE, Palmer WC. Update on the diagnosis and treatment of cholangiocarcinoma[J]. Curr Gastroenterol Rep, 2017, 19(1):2.
[11]	Aguda BD, del Rosario RC, Chan MW. Oncogene-tumor suppressor gene feedback interactions and their control[J]. Math Biosci Eng, 2015, 12(6):1277-1288.
[12]	Scaletta G, Plotti F, Luvero D, et al. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review[J]. Expert Rev Anticancer Ther, 2017, 17(9):827-839.
[13]	Guo Q, Jian Z, Jia B, et al. CXCL7 promotes proliferation and invasion of cholangiocarcinoma cells[J]. Oncol Rep, 2017, 37(2): 1114-1122.
[14]	Han S, Wang D, Tang G, et al. Suppression of miR-16 promotes tumor growth and metastasis through reversely regulating YAP1 in human cholangiocarcinoma[J]. Oncotarget, 2017, 8(34):56635-56650.
[15]	Long HD, Ma YS, Yang HQ, et al. Reduced hsa-miR-124-3p levels are associated with the poor survival of patients with hepatocellular carcinoma[J]. Mol Biol Rep, 2018, 45(6):2615-2623.
[16]	Zhang Y, Zhang D, Lv J, et al. MiR-125a-5p suppresses bladder cancer progression through targeting FUT4[J]. Biomed Pharmacother, 2018(108):1039-1047.
[17]	Wan P, Chi X, Du Q, et al. miR-383 promotes cholangiocarcinoma cell proliferation, migration, and invasion through targeting IRF1[J]. J Cell Biochem, 2018, 119(12):9720-9729.
[18]	Wu YF, Li ZR, Cheng ZQ, et al. Decrease of miR-622 expression promoted the proliferation, migration and invasion of cholangiocarcinoma cells by targeting regulation of c-Myc[J]. Biomed Pharmacother, 2017(96):7-13.
[19]	Wang P, Lv L. miR-26a induced the suppression of tumor growth of cholangiocarcinoma via KRT19 approach[J]. Oncotarget, 2016, 7(49):81367-81376.
[20]	Zheng J, Wu C, Xu Z, et al. Hepatic stellate cell is activated by microRNA-181b via PTEN/Akt pathway[J]. Mol Cell Biochem, 2015, 398(1/2):1-9.

[1]	应康, 杨璨莹, 刘凤珍, 陈丽丽, 刘燕娜. 左心室心肌应变对无症状重度主动脉瓣狭窄患者的预后评估价值[J]. 中华医学超声杂志（电子版）, 2023, 20(06): 581-587.
[2]	李越洲, 张孔玺, 李小红, 商中华. 基于生物信息学分析胃癌中PUM的预后意义[J]. 中华普通外科学文献(电子版), 2023, 17(06): 426-432.
[3]	张俊, 罗再, 段茗玉, 裘正军, 黄陈. 胃癌预后预测模型的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 456-461.
[4]	杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[5]	栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[6]	马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[7]	江振剑, 蒋明, 黄大莉. TK1、Ki67蛋白在分化型甲状腺癌组织中的表达及预后价值研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 623-626.
[8]	晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[9]	鲁鑫, 许佳怡, 刘洋, 杨琴, 鞠雯雯, 徐缨龙. 早期LC术与PTCD续贯LC术治疗急性胆囊炎对患者肝功能及预后的影响比较[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 648-650.
[10]	姜明, 罗锐, 龙成超. 闭孔疝的诊断与治疗：10年73例患者诊疗经验总结[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 706-710.
[11]	钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
[12]	胡宝茹, 尚乃舰, 高迪. 中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 399-403.
[13]	李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[14]	王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[15]	索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Expression and function of miR-181b in cholangiocarcinoma patients

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Expression and function of miR-181b in cholangiocarcinoma patients